PURPOSE: Overexpression of DJ-1 was associated with metastatic uveal melanoma (UM). The purpose of this study was to evaluate the potential of serum DJ-1 as a biomarker for metastasis of uveal melanoma. METHODS: Serum DJ-1 levels were determined by ELISA assays in 27 patients with metastatic UM metastatic uveal melanoma and in 76 patients who were disease free for at least 10 years and 30 age- and sex-matched controls. Receiver operating characteristic (ROC) curve was used to evaluate the feasibility of DJ-1 in detection of metastatic uveal melanoma. RESULTS: Serum DJ-1 levels were significantly higher in patients with metastatic UM compared with patients who were disease free for at least 10 years (P < 0.001) or with controls (P < 0.001). ROC curve for DJ-1 revealed an area under the curve of 86.3%, and when 3.350 ng/mL was used as the cutoff value, a sensitivity of 74.1% and a specificity of 94.3% were achieved. Comparison of DJ-1 and liver function tests (LFTs) ROC curves indicated that DJ-1 was superior to LFTs in detection of metastatic UM. CONCLUSIONS: Our data suggest that DJ-1 might be a promising serum marker for monitoring metastatic uveal melanoma.
PURPOSE: Overexpression of DJ-1 was associated with metastatic uveal melanoma (UM). The purpose of this study was to evaluate the potential of serum DJ-1 as a biomarker for metastasis of uveal melanoma. METHODS: Serum DJ-1 levels were determined by ELISA assays in 27 patients with metastatic UM metastatic uveal melanoma and in 76 patients who were disease free for at least 10 years and 30 age- and sex-matched controls. Receiver operating characteristic (ROC) curve was used to evaluate the feasibility of DJ-1 in detection of metastatic uveal melanoma. RESULTS: Serum DJ-1 levels were significantly higher in patients with metastatic UM compared with patients who were disease free for at least 10 years (P < 0.001) or with controls (P < 0.001). ROC curve for DJ-1 revealed an area under the curve of 86.3%, and when 3.350 ng/mL was used as the cutoff value, a sensitivity of 74.1% and a specificity of 94.3% were achieved. Comparison of DJ-1 and liver function tests (LFTs) ROC curves indicated that DJ-1 was superior to LFTs in detection of metastatic UM. CONCLUSIONS: Our data suggest that DJ-1 might be a promising serum marker for monitoring metastatic uveal melanoma.
Authors: Hang Liu; Min Wang; Min Li; Donghai Wang; Qing Rao; Yang Wang; Zhifang Xu; Jianxiang Wang Journal: Biochem Biophys Res Commun Date: 2008-08-21 Impact factor: 3.575
Authors: Raymond H Kim; Malte Peters; YingJu Jang; Wei Shi; Melania Pintilie; Graham C Fletcher; Carmela DeLuca; Jennifer Liepa; Lily Zhou; Bryan Snow; Richard C Binari; Armen S Manoukian; Mark R Bray; Fei-Fei Liu; Ming-Sound Tsao; Tak W Mak Journal: Cancer Cell Date: 2005-03 Impact factor: 31.743
Authors: D Nagakubo; T Taira; H Kitaura; M Ikeda; K Tamai; S M Iguchi-Ariga; H Ariga Journal: Biochem Biophys Res Commun Date: 1997-02-13 Impact factor: 3.575
Authors: Sophie Vasseur; Samia Afzal; Joël Tardivel-Lacombe; David S Park; Juan Lucio Iovanna; Tak Wah Mak Journal: Proc Natl Acad Sci U S A Date: 2009-01-14 Impact factor: 11.205
Authors: Annett Linge; Susan Kennedy; Deirdre O'Flynn; Stephen Beatty; Paul Moriarty; Michael Henry; Martin Clynes; Annemarie Larkin; Paula Meleady Journal: Invest Ophthalmol Vis Sci Date: 2012-07-09 Impact factor: 4.799
Authors: Elisa Turriani; Diana F Lázaro; Sergey Ryazanov; Andrei Leonov; Armin Giese; Margarete Schön; Michael P Schön; Christian Griesinger; Tiago F Outeiro; Donna J Arndt-Jovin; Dorothea Becker Journal: Proc Natl Acad Sci U S A Date: 2017-06-05 Impact factor: 11.205